Patents Assigned to Hematronix Inc.
  • Patent number: 6653063
    Abstract: A hematology control composition and method of making the composition is provided. The control employs a plurality of components including a synthetic plasma component, a red blood cell component, a platelet component and a leukocyte component. The leukocyte component includes at least one subpopulation having particles derived from other than white blood cells.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: November 25, 2003
    Assignee: Hematronix, Inc.
    Inventors: Frank J. Carver, James D. Lapicola
  • Publication number: 20030104631
    Abstract: The present invention provides a method for preparing cells for use in a hematology blood control. The preparation steps, namely the use of cross-linking agents such as aldehydes, involve a step-wise process starting with very low concentrations of a cross-linking agent. Successive fixations involve an increase in the concentration of cross-linking agent.
    Type: Application
    Filed: January 6, 2003
    Publication date: June 5, 2003
    Applicant: Hematronix, Inc.
    Inventors: Franklin J. Carver, James D. Lapicola
  • Patent number: 6514763
    Abstract: The control of the present invention involves a gentle chemical removal of red cells, leaving an intact white cell preparation. The preservation steps, namely the use of cross-linking agents as aldehydes, involve a step-wise process starting with very low concentrations of a cross-linking agent. The fixation part of the process outlined in this disclosure has also been applied to non-mammalian blood cells and therefor would appear to be a universal procedure for preparing all types of vertebrate blood cells.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: February 4, 2003
    Assignee: Hematronix, Inc.
    Inventors: Franklin J. Carver, James D. Lapicola
  • Patent number: 6342391
    Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate (ESR) control having the following three components: (1) a synthetic plasma base, (2) an aggregating agent such as a high molecular weight polymer or combination of high molecular weight polymers, and (3) chemically fixed mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens. Chemical fixing of the red blood cells provides the ESR control with the capability of providing useful results in the presence of citrate and/or saline.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: January 29, 2002
    Assignees: Streck Laboratories, Inc., Hematronix Inc.
    Inventors: Roulhwai Chen, Azra S. Zaidi
  • Patent number: 6331435
    Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate control having the following three components: (1) a synthetic plasma base, (2) a high molecular weight polymer, and (3) mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: December 18, 2001
    Assignees: Streak Laboratories, Inc., Hematronix Inc.
    Inventor: Wayne R. Hengstenberg
  • Patent number: 6146901
    Abstract: A composition and a method for using the composition for manipulating the electronic and optical properties of biological particles are disclosed. The composition generally has a hypotonic buffering solution, a polyhydroxy alcohol, a stabilizing agent, and, in some applications, a non-ionic surfactant. By varying the relative concentrations of these components and by adjusting the timing of their combination and interaction, the composition and method allow for the alteration of the electronic and optical properties of the particles to achieve target values for the properties. In one particularly advantageous application, the composition and method of the invention allow for the creation of selected analogs for the subpopulations of human leukocytes from a single biological particle for use as a control product in differentiating particle analyzers.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: November 14, 2000
    Assignee: Hematronix, Inc.
    Inventors: Franklin J. Carver, James D. Lapicola, Lorraine A. Granier
  • Patent number: 6051433
    Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate control having the following three components: (1) a synthetic plasma base, (2) a high molecular weight polymer, and (3) mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: April 18, 2000
    Assignees: Streck Laboratories, Inc., Hematronix, Inc.
    Inventor: Wayne R. Hengstenberg
  • Patent number: 6017764
    Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate (ESR) control having the following three components: (1) a synthetic plasma base, (2) an aggregating agent such as a high molecular weight polymer or combination of high molecular weight polymers, and (3) chemically fixed mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens. Chemical fixing of the red blood cells provides the ESR control with the capability of providing useful results in the presence of citrate and/or saline.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: January 25, 2000
    Assignees: Streck Laboratories, Inc., Hematronix, Inc.
    Inventors: Roulhwai Chen, Azra S. Zaidi
  • Patent number: D306649
    Type: Grant
    Filed: November 2, 1987
    Date of Patent: March 13, 1990
    Assignee: Hematronix, Inc.
    Inventors: James D. Lapicola, William C. Buxbaum